Procarbazine, lomustine and vincristine for recurrent high-grade glioma

John L. Villano, Myrna Rosenfeld, Saurabh Parasramka

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


This is the protocol for a review and there is no abstract. The objectives are as follows: To assess effectiveness and safety of procarbazine, lomustine, and vincristine chemotherapy (PCV) chemotherapy with other intervention groups in people with recurrent high-grade glioma (HGG). To investigate whether predefined subgroups of people benefit more or less from chemotherapy.

Original languageEnglish
Article numberCD011773
JournalCochrane Database of Systematic Reviews
Issue number6
StatePublished - Jun 25 2015

Bibliographical note

Funding Information:
We would like to thank and acknowledge the Cochrane Neuro-oncology Group for their support. We would also like to acknowledge funding support from the Society of Neuro-oncology (SNO).

Funding Information:
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health.

Publisher Copyright:
© 2015 The Cochrane Collaboration.

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Procarbazine, lomustine and vincristine for recurrent high-grade glioma'. Together they form a unique fingerprint.

Cite this